Medivir (DB:MVR0) - Aandelenkoers, Nieuws & Analyse

MVR0 Overzicht aandelen

Medivir AB (publ), een farmaceutisch bedrijf, richt zich op de ontwikkeling en commercialisering van behandelingen voor kanker in Scandinavië, de rest van Europa en internationaal. Meer informatie

MVR0 fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 66.23% per jaar groeien

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( SEK7M )

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Heeft minder dan 1 jaar cash runway

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

+ 2 meer risico's

Medivir AB (publ) Concurrenten

Medigene

XTRA:MDG1

€22.6m

Heidelberg Pharma

XTRA:HPHA

€103.9m

co.don

XTRA:CNW

€6.5m

2invest

XTRA:2INV

€63.8m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Medivir
Historische aandelenkoersen
Huidige aandelenkoers	SEK 0.22
52 Week Hoogtepunt	SEK 0.43
52 Week Laag	SEK 0.19
Bèta	-0.23
11 maand verandering	1.41%
3 maanden verandering	-13.94%
1 Jaar Verandering	-25.44%
33 jaar verandering	-78.40%
5 jaar verandering	-89.49%
Verandering sinds IPO	-99.33%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	MVR0	DE Biotechs	DE Markt
7D	5.4%	-0.7%	0.2%
1Y	-25.4%	-17.2%	8.5%

Rendement versus industrie: MVR0 presteerde slechter dan de German Biotechs -sector, die het afgelopen jaar een rendement van -17.2 % opleverde.

Rendement versus markt: MVR0 presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 8.5 % opleverde.

Prijsvolatiliteit

Is MVR0's price volatile compared to industry and market?
MVR0 volatility
MVR0 Average Weekly Movement	12.4%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.3%

Stabiele aandelenkoers: De aandelenkoers van MVR0 is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 12% ) van MVR0 is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen German.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1987	10	Jens Lindberg	www.medivir.com

Medivir AB (publ), een farmaceutisch bedrijf, richt zich op de ontwikkeling en commercialisering van kankerbehandelingen in Scandinavië, de rest van Europa en internationaal. Het bedrijf brengt Xerclear op de markt voor de behandeling van herpes labialis onder de naam Zoviduo. Het ontwikkelt ook Remetinostat voor de behandeling van MF cutaan T-cel lymfoom en basaalcelcarcinoom, evenals plaveiselcelcarcinoom.

Medivir AB (publ) Samenvatting

Hoe verhouden de winst en inkomsten van Medivir zich tot de beurswaarde?
MVR0 fundamentele statistieken
Marktkapitalisatie	€26.43m
Inkomsten(TTM)	-€10.17m
Inkomsten(TTM)	€611.48k

43.2x

P/S-verhouding

-2.6x

Koers/Winstverhouding

Is MVR0 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
MVR0 resultatenrekening (TTM)
Inkomsten	SEK 7.03m
Kosten van inkomsten	SEK 97.07m
Brutowinst	-SEK 90.03m
Overige uitgaven	SEK 26.89m
Inkomsten	-SEK 116.92m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

Feb 18, 2025

Winst per aandeel (EPS)	-1.04
Brutomarge	-1,280.14%
Nettowinstmarge	-1,662.48%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde MVR0 op de lange termijn?

Bekijk historische prestaties en vergelijking

MVR0 Overzicht aandelen

Beloningen

Risicoanalyse

Medivir AB (publ) Concurrenten

XTRA:MDG1

€22.6m

XTRA:HPHA

€103.9m

XTRA:CNW

€6.5m

XTRA:2INV

€63.8m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Third quarter 2024 earnings released: kr0.30 loss per share (vs kr0.42 loss in 3Q 2023)

Medivir AB (Publ) Appoints Nomination Committee

Medivir Presents Positive, Mature Data from its Ongoing Phase 1b / 2a Study of fostroxacitabine bralpamide (fostrox) + Lenvima in Advanced Liver Cancer (hepatocellular carcinoma/HCC) at the European Society of Medical Oncology Congress

Medivir AB to Present Mature Clinical Data for Fostrox + Lenvima at ESMO Conference

Second quarter 2024 earnings released: kr0.32 loss per share (vs kr0.48 loss in 2Q 2023)

Medivir AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Recent updates

Third quarter 2024 earnings released: kr0.30 loss per share (vs kr0.42 loss in 3Q 2023)

Medivir AB (Publ) Appoints Nomination Committee

Medivir Presents Positive, Mature Data from its Ongoing Phase 1b / 2a Study of fostroxacitabine bralpamide (fostrox) + Lenvima in Advanced Liver Cancer (hepatocellular carcinoma/HCC) at the European Society of Medical Oncology Congress

Medivir AB to Present Mature Clinical Data for Fostrox + Lenvima at ESMO Conference

Second quarter 2024 earnings released: kr0.32 loss per share (vs kr0.48 loss in 2Q 2023)

Medivir AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Medivir AB to Present Updated Clinical Data for Fostrox + Lenvima in Hepatocellular Cancer At ESMO Conference in September Stockholm

New major risk - Financial position

Medivir AB Presents Positive New Data from Its Ongoing Phase Ib / IIa Study of Fostroxacitabine Bralpamide (Fostrox) + Lenvima® in Advanced Hepatocellular Carcinoma (HCC)

Medivir Selects Global CRO Partner for Upcoming Phase 2B Study in HCC with fostrox + Lenvima and Initiates Study Feasibility

Medivir Aktiebolag (publ) Approves Board Appointments

First quarter 2024 earnings released: kr0.23 loss per share (vs kr0.34 loss in 1Q 2023)

Full year 2023 earnings released: kr1.22 loss per share (vs kr1.59 loss in FY 2022)

Medivir AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

New major risk - Shareholder dilution

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

Medivir Presents the First Clinical Data with Fostrox + Lenvima At the Asco GI Scientific Congress

Medivir AB Announces Further Improved Clinical Benefit with Fostrox + Lenvima as Data from the Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancer

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 128.961315 million.

Medivir AB Announces Data from Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancers

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 147.979713 million.

Third quarter 2023 earnings released: kr0.42 loss per share (vs kr0.27 loss in 3Q 2022)

Medivir AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

Medivir AB (publ) to Report Q1, 2024 Results on Apr 30, 2024

Medivir AB (publ), Annual General Meeting, May 07, 2024

Medivir AB (Publ) Announces Resignation of Anette Lindqvist as Director

Medivir AB Announces All Patients in the Ongoing Phase 2A Study in Advanced Hepatocellular Car Car Car Carcinoma Has Now Dosed At Least Two Treatment Cycle

Medivir AB Reports Promising Interim Data, Including A First Complete Response in Phase 1B/2A Hcc Study with Fostrox in Combination with Lenvima

High number of new and inexperienced directors

Second quarter 2023 earnings released: kr0.48 loss per share (vs kr0.41 loss in 2Q 2022)

Medivir AB Announces 15th Patient with Advanced Liver Cancer Has Been Included in the Ongoing Phase 2A Study

Medivir AB Announces Formation of A Scientific Advisory Council

Medivir AB Announces Patent Application for Fostrox Approval in China

Medivir AB Completes the Dose Escalation Part (Phase 1B) of the 1B/2A Study in Hcc and Focus on the Combination of Fostrox and Lenvima

Full year 2022 earnings released: kr1.59 loss per share (vs kr1.20 loss in FY 2021)

Forecast to breakeven in 2024

Less than half of directors are independent

Medivir Completes A Successful Pre-IND Meeting with the FDA

Medivir AB (Publ) Appoints Pia Baumann as New Chief Medical Officer

Medivir AB (Publ) Appoints Nomination Committee

Medivir AB (publ) to Report Q2, 2023 Results on Aug 18, 2023

Medivir AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Medivir Aktiebolag (Publ) Announces Board Changes

Medivir AB (publ) to Report Fiscal Year 2021 Final Results on Apr 05, 2022

Medivir AB (Publ) Announces Phase II Study of Miv-711 for Osteoarthritis Shows Statistically Significant Reduction in Oa Pain

Medivir AB (publ) Announces Abstract for MIV-818 phase 1b monotherapy for ESMO Congress published

Medivir AB Announces Positive Data from the Remetinostat Phase II Study in Basal Cell Carcinoma Published in Clinical Cancer Research

Medivir Announces the Design of its Upcoming MIV-818 Combination Study

Medivir AB Announces Positive Results from Investigator-Initiated Phase II Clinical Study of Remetinostat in Patients with Squamous Cell Carcinoma

Medivir AB (publ), Annual General Meeting, May 05, 2021

Medivir AB Announces Delisting of Paid Subscription Shares

Medivir AB Enters into Licensing Agreement with Ubiquigent Limited for Preclinical Program USP7

New 90-day low: €0.79

IGM Biosciences, Inc. Enters into Exclusive Licensing Agreement with Medivir for Birinapant

New 90-day low: €0.80

Medivir AB (Publ) Renegotiates its agreement with TetraLogic Pharmaceuticals Corporation